ANTICANCER RESEARCH
International Journal of Cancer Research and Treatment
ISSN: 0250-7005

ANTICANCER RESEARCH is an independent international forum devoted to the rapid publication of original high quality articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months from acceptance are guaranteed.

Selection of Recent Articles


Bortezomib Therapeutic Effect Is Associated with Expression of FGFR3 in Multiple Myeloma Cells. M. GUAN, L. ZHU, G. SOMLO, A. HUGHES, B. ZHOU, Y. YEN (Duarte, CA, USA; Zhejiang, China)

Utilization of a Right-handed Coiled-coil Protein from Archaeabacteria Staphylothermus marinus as a Carrier for Cisplatin. M. ERIKSSON, S. HASSAN, R. LARSSON, S. LINDER, T. RAMQVIST, H. LOVBORG, T. VIKINGE, J. FIGGEMEIER, J. MÜLLER, J. STETEFELD, T. DALIANIS, S. ÖZBEK (Stockholm; Uppsala; Linköping, Sweden; Basel, Switzerland; Winnipeg, Manitoba, Canada; Heidelberg, Germany)


Analysis of Factors Influencing Dysphagia Severity Following Treatment of Head and Neck Cancer. N.P. NGUYEN, C. FRANK, C.C. MOLTZ, U. KARLSSON, P.D. NGUYEN, H.W.C. WARD, P. VOS, H.J. SMITH, S. HUANG, L.M. NGUYEN, C. LEMANSKI, A. LUDIN, S. SALLAH (Tucson, AZ; Dallas, TX; Greenville, NC; Ann Arbor, MI; Cleveland, OH, USA; Montpellier, France; Athens, Greece)

The Hedgehog Signaling Pathway Plays an Essential Role in Maintaining the CD44+CD24-/low Subpopulation and the Side Population of Breast Cancer Cells. H. TANAKA, M. NAKAMURA, C. KAMEDA, M. KUBO, N. SATO, S. KUROKI, M. TANAKA, M. KATANO (Fukuoka, Japan)

A Role for the Substance P/NK-1 Receptor Complex in Cell proliferation in Oral Squamous Cell Carcinoma. S. BRENER, M.A. GONZÁLEZ-MOLES, D. TOSTES, F. ESTABAN, J.A. GIL-MONTOYA, I. RUIZ-ÁVILA, M. BRAVO, M. MUÑOZ (Sao Paulo, Brazil; Granada; Sevilla; Jaen, Spain)

Comparison of Cell Death-inducing Effect of Novel Taxane SB-T-1216 and Paclitaxel in Breast Cancer Cells. J. KOVÁ, M. EHRICHOVÁ, B. ŠMEJKALOVÁ, I. ZANARDI, I. OJIMA (Prague, Czech Republic; Stony Brook, NY, USA)

Conversion from Calcineurin Inhibitors to Sirolimus Reduces Vascularization and Thickness of Post-transplant Cutaneous Squamous-cell Carcinomas. A.-L. RIVAL-TRINGALI, S. EUVRARD, E. DECULLIER, A. CLAUDY, M. FAURE, J. KANITAKIS (Lyon, France)

Vessel Dilator and Kaliuretic Peptide Inhibit Ras in Human Prostate Cancer Cells. Y. SUN, E.J. EICHELBAUM, W.P. SKELTON IV, A. LENZ, H. WANG, D.L. VESELY (Tampa, FL, USA)

Pharmacological Interplay between Breast Cancer Resistance Protein and Gefitinib in Epidermal Growth Factor Receptor Signaling. K. KATAYAMA, K. SHIBATA, J. MITSUHASHI, K. NOGUCHI, Y. SUGIMOTO (Tokyo, Japan)


Editorial Office: Manuscripts and correspondence should be addressed to: Dr. John G. Delinassios, Managing Editor, Anticancer Research, Editorial Office, International Institute of Anticancer Research (IIAR), 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki 19014, Greece.

Tel & Fax: +30-22950-53389, e-mail: journals@iiar-anticancer.org

For more information about Anticancer Research and IIAR, please visit the IIAR website: www.iiar-anticancer.org
Instructions to Authors

**General Policy.** IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research. The principal aim of IN VIVO is to provide for the prompt publication of accepted articles, generally within 1-2 months from final acceptance.

Manuscripts will be accepted on the understanding that they report original unpublished works that are not under consideration for publication by another journal, and that they will not be published again in the same form.

All material submitted to IN VIVO will be subject to review, when appropriate, by two members of the Editorial Board. The Editors reserve the right to improve manuscripts on grammar and style.

The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and at all times the animals must be treated humanely. The Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society must be followed.

The Editors and Publishers of IN VIVO accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrantee due diligence in the creation and issuance of their work.

**NIH Open Access Policy.** The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in IN VIVO, for public archiving in PubMed Central.

**Copyright.** Once a manuscript has been published in IN VIVO, which is a copyrighted publication, the legal ownership of all published parts of the paper has passed from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without written consent of the Managing Editor.

**Format.** Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) short papers. Additionally, the Editors may invite review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

**Manuscripts.** Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author’s opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

**Figures.** All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, and not photographic copies. Colour plates are charged.

**Tables.** Each table should be submitted on a separate page, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.
Nomenclature and Abbreviations. Nomenclature should follow that given in "Chemical Abstracts". Standard abbreviations will be preferable. If a new abbreviation is used, it must be defined at its first usage.


Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “NCT”). Please note that there is no space between the prefix “NCT” and the number. Example: NCT00001789.

Submission of Manuscripts. Follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your articles twice.):

1. To submit your article online please visit: IIAR-Submissions (link to: http://www.iiar-anticancer.org/submissions/login.php)
2. You can send your article via e-mail to journals@iiar-anticancer.org (mail to: journals@iiar-anticancer.org). Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies of your manuscript to the following address:
   John G. Delinassios
   International Institute of Anticancer Research (IIAR)
   Editorial Office of ANTICANCER RESEARCH,
   IN VIVO and CANCER GENOMICS & PROTEOMICS
   1st km Kapandritiou-Kalamou Road
   P.O. Box 22, GR-19014 Kapandriti, Attiki
   GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

Reprints. Twenty-five copies of each communication will be provided free-of-charge. Additional copies or PDF files may be ordered after the acceptance of the paper. Requests for additional reprints should be addressed to the Editorial Office.

Copyright © 2009 International Institute of Anticancer Research (J.G. Delinassios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.
I am one of the authors of the article published in IN VIVO Vol. 23 (2009), pp. .........., year ...........

Please send me previous Volume No(s) ................. at Euro 108.00 per volume.

Please enter my personal subscription to IN VIVO 2009 (Volume 23) at the special Author’s rate of Euro 216.00 (print or online); Euro 300.00 (print & online).

Please enter a Subscription to IN VIVO for Volume 23 (2009).

Payment is enclosed.

Please invoice.

(cheques should be made payable to J.G. Delinassios, Athens, Greece)

Please send me the following previous volumes (1-22) at 50% discount on the above rates.

Name and Address:

Tel: ........................................................................................................................................................................................................
Fax: ........................................................................................................................................................................................................
Signature: ...................................................................................................................................................................................................
Date: ......................................................................................................................................................................................................

Please send this order to IN VIVO, Editorial Office, IIAR, 1st km Kapandriou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki 19014, Greece. Tel & Fax: +30-22950-53389, e-mail: journals@iiar-anticancer.org


Re-evaluation of Anti-inflammatory Activity of Mastic Using Activated Macrophages. L. ZHOU, K. SATOH, K. TAKAHASHI, S. WATANABE, W. NAKAMURA, J. MAKI, H. HATANO, F. TAKEKAWA, C. SHIMADA, H. SAKAGAMI (Saitama; Tokyo; Fukushima; Ehime, Japan) .................................................. 583

Early Modification of c-myc, Ha-ras and p53 Expressions by Chemical Carcinogens (DMBA, MNU). F. BUDÁN, T. VARJAS, G. NOWRASTEH, I. PRANTNER, Z. VARGA, Á. EMBER, J. CSEH, K. GOMBOS, E. PÁSZIT, G. GŐBEL, M. BAUER, T. GRACZA, I. ARANY, P. PERJÉSI, I. EMBER, I. KISS (Pécs; Székesfehérvár; Miskolc, Hungary; Jackson, MS, USA) ........................................................................................................ 591

* Review. Vitamin Free Radicals and their Anticancer Action. N. GETOFF (Vienna, Austria) ................................................................. 599

Involvement of Matrix Metalloproteinases in the Inhibition of Cell Invasion and Migration Through the Inhibition of NF-κB by the New Synthesized Ethyl 2-[(N-p-chlorobenzyl-(2’-methyl)]anilino-4-oxo-4,5-dihydrofuran-3-carboxylate (JOTO1007) in Human Cervical Cancer Ca Ski Cells. A.-C. HUANG, S.-C. HSU, C.-L. KUO, C.-L. LIAO, K.-C. LAI, T.-P. LIN, S.-H. WU, H.-F. LU, N.-Y. TANG, J.-S. YANG, J.-G. CHUNG (Yilan; Taichung; Yunlin; Changhua; Taipei, Taiwan) ........................................................................................................ 613

Clinical Studies

Increased D-Lactic Acid Intestinal Bacteria in Patients with Chronic Fatigue Syndrome. J.R. SHEEDY, R.E.H. WETTENHALL, D. SCANLON, P.R. GOOLEY, D.P. LEWIS, N. MCGREGOR, D.I. STAPLETON, H.L. BUTT, K.L. DE MEIRLEIR (Parkville; Donvale, Victoria, Australia; Brussels, Belgium) ................................................................. 621


Pneumonitis Related to Docetaxel: Case Report and Review of the Literature. S. ALSAMARAI, A.G. CHARPIDOU, R.A. MATTHAY, D. CONFELD, K.N. SYRIGOS, M.W. SAIF (New Haven, CT, USA; Athens, Greece) ........................................................................................................ 635


Cytoreductive Surgery (CS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Treatment of Peritoneal Surface Malignances: Report of a Phase II Clinical Study. S. ASERO, M. CARUSO, N. VALLONE, A.G. LUCIANI, V. LOMBARDO, G. TERRANOVA, G. ETTORE, G. GIANNONE (Catania, Italy) ........................................................................................................ 645


* Reviews (pages 507, 599)